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EXPERT REVIEWEpithelial to mesenchymal transition: The doorway to metastasis in
human lung cancersChadrick E. Denlinger, MD, John S. Ikonomidis, MD, PhD, Carolyn E. Reed, MD, and
Francis G. Spinale, MD, PhDLung cancer remains a disease characterized by early metas-
tasis and poor 5-year survival. Lung cancers are almost ex-
clusively derived from epithelial tissues, and most tumor
cells retain epithelial characteristics even as the tumor prog-
resses. Small numbers of cells, however, are thought to un-
dergo a process of epithelial to mesenchymal transition in
which the malignant cells acquire a fibroblastlike morphol-
ogy, lose intracellular adhesions, and become mobile. This
process represents a crucial event in cancer invasion and me-
tastasis. These mesenchymal cells may subsequently revert
to an epithelial phenotype, allowing clinically relevant
growth of metastases. Ongoing studies are required to deter-
mineways in which the process of epithelial tomesenchymal
transition can be exploited in patients with lung cancer for
screening, diagnostic studies, and therapeutic options.
Lung cancer remains the most common cause of
malignancy-related death among both men and women in
America with more people dying of lung cancer than of mel-
anoma, colorectal, breast, and prostate cancers combined.1
The overall 5-year survival among patients with non–small
cell lung cancer (NSCLC) remains a dismal 15%, primarily
from development of distant metastatic disease. Despite the
expectation that curative surgical resection of early stage
NSCLC leaves patients disease free, 40% to 60% of these
patients still have metastases develop and die of lung cancer.
Efficacy of the best available chemotherapeutic agents to
control metastasis has reached a plateau, and further ad-
vancement of cytotoxic therapy is unlikely. More recently,
targeted agents have attracted interest after the introduction
of antibodies and small molecule inhibitors of epithelial
growth factor receptor and vascular endothelial growth fac-
tor. Novel agents delivered against these receptors provide
survival benefits only among select patients, however,
and the application of targeted agents to the overall popula-
tion of patients with lung cancer provides only modest
benefits.2,3
Recently, the concept of epithelial to mesenchymal transi-
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The Journal of Thoracic and Catumor invasion and metastasis in numerous types of solid tu-
mors, including NSCLC, on the basis of clinical observa-
tions and laboratory investigations.4 EMT is a normal
physiologic process that is essential for development as
embryos progress from single-layered to multilayered or-
ganisms. EMT remains critical during development for the
migration of some cells, such as neural crest cells, through-
out the body. Even in adulthood, the induction of EMT
remains a natural and necessary component of the inflamma-
tory process and normal wound healing.5 The phenomenon
of EMT has therefore been subdivided into 3 separate
classes: class 1 EMT is involved with embryologic develop-
ment, class 2 EMT is involved with wound healing, and
class 3 EMT is involved with cancer cell invasion and
migration.
Expression of mesenchymal markers among small clus-
ters of cells within epithelium-derived tumors has been
well described and is thought by some to represent a crucial
event in malignancy that is required for local invasion and
establishment of distant metastasis.6 Markers for EMT in hu-
man tissue specimens have been correlated with increased
risk of cancer recurrence, the presence of metastasis, and de-
creased survival, supporting the concept that EMT events
represent an aggressive biologic transition. This review
provides an overview of our current understanding of the
process of EMT in lung cancer and highlights the need for
further investigations in this area by clinician–scientists.
The goal is to identify ways in which EMT can be exploited
for therapeutic benefits.
Evidence supporting the EMT hypothesis includes the ob-
servation of malignant cells with a mesenchymal phenotype
in areas of carcinomas located at the advancing tumor front,
where malignant cells infiltrate surrounding normal tissues.
In addition, the ability to manipulate carcinoma cells in vitro
into adopting mesenchymal phenotypes by the forced over-
expression of EMT-linked transcription factors provides
convincing evidence that EMT does occur. The clinical
relevance of EMT in lung and other cancers is supported
by the prognostic implications of mesenchymal markers
within the primary tumor. Importantly, the presence of
EMT cells within tumors has been correlated with the exis-
tence of metastasis,7 an increased risk of cancer recurrence,8
and decreased patient survival.9,10
Despite evidence supporting the hypothesis that EMT
conveys enhanced invasiveness and metastasis, the concept
remains controversial for several reasons. Most importantly,
the EMT phenomenon does not conform to the canonicalrdiovascular Surgery c Volume 140, Number 3 505
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E47 ¼ basic helix-loop-helix transcription
factor (E2A gene product)
ECM ¼ extracellular matrix
EMT ¼ epithelial to mesenchymal transition
GSK-3b ¼ glycogen synthase kinase-3b
IL ¼ interleukin
MET ¼ mesenchymal to epithelial transition
MMP ¼ matrix metalloproteinase
MT1-MMP ¼ membrane type 1 matrix
metalloproteinase
NSCLC ¼ non–small cell lung cancer
SMAD ¼ family of proteins originally
identified as class of proteins related
to Sma and Mothers against decap-
entaplegic protein
TGFb ¼ Transforming growth factor bbelief that cancers evolve by progressively acquiring genetic
mutations that convey an increasingly aggressive pheno-
type. Instead, EMT events are transient changes driven by
signals derived from the extracellular matrix (ECM) and in-
flammatory cells recruited to the advancing tumor front.
Therefore, mesenchymal cells revert back to an epithelial
form when signals driving the mesenchymal transition dissi-
pate. The transient nature of EMT events makes scientific in-
vestigation of this phenomenon difficult for 2 reasons. First,
transformed mesenchymal cells in human tumor specimens
represent only a small percentage of the entire tumor, and
therefore they can only be reliably identified by examining
entire tissue slides, rather than representative samples in
tissue microarrays. Similarly, because large segments of
tumors do not uniformly undergo EMT, it is impossible to
capture large numbers of transformed mesenchymal cells
in vivo, as in frozen tumor samples, for investigation.
Much of what has been learned about the EMT phenomenon
has therefore come through in vitro investigations that have
been correlated with clinical observations in tumor
specimens.
EMTAS A MARKER FOR POOR PROGNOSIS
Malignant tumor cells with a mesenchymal phenotype ap-
pear clinically relevant, because the presence of EMT cells
within primary tumors has been associated with worse clin-
ical outcomes. The presence of transformed mesenchymal
cells within tumors correlates with an increased risk of can-
cer recurrence and negatively relates to long-term survival
among patients with numerous different types of solid tumor
malignancies, including colorectal cancer,7 gastric cancer,11
and NSCLC,8,9 and is related to recurrent disease among
patients with bladder cancer.8 Furthermore, expression of6 The Journal of Thoracic and Cardiovascular Surgtranscription factors driving the mesenchymal morphology
has been linked to chemoresistance in pancreatic cell lines
and in human specimens.12 In addition to its apparent effect
on traditional cytotoxic agents, the mesenchymal phenotype
also correlates with resistance to the novel epidermal growth
factor receptor inhibitor erlotinib.13 This clinical informa-
tion validates the understanding that EMT represents an ag-
gressive transition of carcinomas into a more strongly
pathologic phenotype.
The presence of EMT cells has also been associated with
an increased rate of metastasis. In colorectal cancers, small
clusters of EMT cells have been described as tumor budding
that can be visualized penetrating normal surrounding tis-
sues in histologic specimens. Tumor buds are highlighted
with immunohistochemical stains for pancytokeratin. By
means of receiver–operator curves, Prall and colleagues14
defined a cutoff value of 25 tumor buds/high-power field
to discriminate a patient population with early-stage colorec-
tal cancer at significantly greater risk for tumor metastasis
and decreased survival than patients with fewer than 25 tu-
mor buds/high-power field. This clinical observation further
supports the concept that EMT contributes to tumor metas-
tasis in patients with solid tumors.
Numerous biochemical markers for the induction of EMT
have been described. The marker most tightly linked to EMT
is the loss of E-cadherin expression, and the loss of this
marker has been has been associated with an increased
rate of metastasis among patients with breast cancer.15 Sim-
ilarly, EMT markers have also been correlated with worse
outcomes among patients with lung cancer. The expression
in NSCLC tumor specimens of Slug, a transcription factor
known to downregulate E-cadherin expression, correlates
with an increased rate of cancer recurrence and decreased
survival.10 Furthermore, forced overexpression of Slug in
lung cancer cell lines used for the creation of xenografts in
mice demonstrated markedly diminished E-cadherin expres-
sion, significantly enhanced expression of matrix metallo-
proteinase (MMP) 2, and enhanced propensity for
metastases to develop in vivo.10 Collectively, these data sup-
port the concept that EMT events lead to tumor invasion and
metastasis and decreased survival among patients with any
of a multitude of solid tumor malignancies.
Currently, the working model suggests that EMT events
allow malignant cells to disseminate throughout the body.
The histology of established tumor metastases recapitulates
the tissues of origin, however, rather than cells with a mesen-
chymal phenotype. Models of EMT as a prominent mecha-
nism of metastasis suggest that migratory mesenchymal
cells are able to revert back to an epithelial form through
a process of mesenchymal to epithelial transition (MET),
which could explain the epithelial morphology of cells in
metastatic foci of lung cancers and other carcinomas
(Figure 1). Ongoing studies will be required to determine
whether the EMT cells are actually the cells responsibleery c September 2010
FIGURE 1. Local inflammatory cytokines at advancing tumor front play critical role in inducing biochemical and morphologic changes in epithelial tumors,
leading to adoption of fibroblastlike mesenchymal form. Transformed mesenchymal cells lose intracellular adhesions and are capable of migrating through
surrounding stroma. In remote locations, mesenchymal cells are thought to revert back to epithelial phenotype, which allows rapid growth and development of
clinically significant metastases. TGFb, Transforming growth factor b.
Denlinger et al Expert Reviewfor development of metastases or whether they are simply
markers for an aggressive tumor that contains other compo-
nents with the propensity to metastasize.
EPITHELIAL TO MESENCHYMALTRANSITION
By definition, all carcinomas, including essentially all lung
cancers, are derived from epithelial tissues. Even as bronchial
epithelial cells become progressively dysplastic and trans-
form into frankly invasive malignant cells, they retain mor-
phologic and architectural characteristics of the epithelial
tissues from which they arose. Most notably, epithelial cells
retain cell polarity and dense cell–cell adherens junctions.
In addition, adenocarcinomas continue to form glandular
structures, and squamous cell carcinomas remain tightly clus-
tered and often produce keratin pearls. Each of these features
is consistent with the epithelial origins of carcinomas.
As tumors progress, clusters of transformed cells most fre-
quently identified at the advancing tumor front undergo
a morphologic transition whereby they lose epithelial char-
acteristics and acquire a mesenchymal phenotype, recogniz-
able by the overall cell appearance, intercellular relations,
and biochemical changes. The transformed mesenchymal
cells lose polarity, become elongated, and are less adherent
to surrounding cells and the ECM. More importantly, mes-
enchymal cells also become motile, which facilitates inva-
sion into local tissues and lymphovascular structures. In
addition to gross morphologic changes in cells that have un-
dergone EMT, several consistent molecular changes have
been described (Figure 2).The Journal of Thoracic and CaMost notably, E-cadherin, which is a cell surface protein
that is an essential component of adherens junctions between
similar cells forming epithelial boundaries, is highly ex-
pressed on the cytoplasmic membrane of epithelial cells.
E-cadherin expression is retained in carcinomas, including
lung cancers, but its expression is lost in cells that have un-
dergone EMT. In fact, E-cadherin loss in carcinoma cells is
considered pathognomonic of the EMT phenomenon, and E-
cadherin is considered to be a ‘‘master regulator’’ of EMT.16
Indeed, most signaling pathways involved in EMT converge
on the regulation of E-cadherin expression. Not only is
E-cadherin loss a marker for EMT, this molecular change
also correlates with increased tumor grade, metastasis, and
mortality.17 Despite tight associations of E-cadherin loss,
the process of EMT, and poor patient outcomes, genetic mu-
tations of E-cadherin are extremely rare in almost every type
of carcinoma, with the exception of lobular breast carcinoma
and diffuse gastric cancer.16 Instead, epigenetic modifica-
tions if the promoter region with hypermethylation are re-
sponsible for the transcriptional suppression of E-cadherin
in EMT cells. Thus in EMT cells, E-cadherin genes are si-
lenced by mechanisms that are completely reversible when
driven by the appropriate stimuli.
A second protein, closely related to E-cadherin, that plays
a functional role in EMT is b-catenin, which is an intracellu-
lar component of adherens junctions. In epithelial cells,
b-catenin colocalizes with E-cadherin to the cytoplasmic
membrane and is critical for linking intercellular adherens
junctions with the intracellular actin cytoskeleton. As cellsrdiovascular Surgery c Volume 140, Number 3 507
FIGURE 2. Interchangeable epithelial and mesenchymal phenotypes are characterized by several biochemical and cell surface protein markers that contrib-
ute to their respective morphologies and biologic activities. EMT, Epithelial to mesenchymal transition; ZEB, zinc finger E-box binding protein; MET, mes-
enchymal to epithelial transition; MT1-MMP, membrane type 1 matrix metalloproteinase; MMP-2, matrix metalloproteinase 2.
Expert Review Denlinger et alundergo EMT and E-cadherin expression is lost, b-catenin
translocates from the cytoplasmic membrane to the nucleus,
where it participates in transcriptional regulation of EMT-
related gene targets. Under normal circumstances, b-catenin
released from the cytoplasmic membrane is rapidly phos-
phorylated by glycogen synthase kinase-3b (GSK-3b), ubiq-
uitinated, and degraded. Activation of the Wnt pathway,
however, a common finding in cells that have undergone
EMT, leads to GSK-3b inhibition, allowing b-catenin accu-
mulation in the cytoplasm and nucleus.18 Nuclear b-catenin
functions as a cofactor for T-cell factor, which drives tran-
scription of genes required for EMT including Ets, Jun,
Slug, matrilysin, fibronectin, and vimentin.19 Similar shut-
tling of b-catenin from the cytoplasmic membrane to the
nucleus during the process of EMT has been described in nu-
merous different solid tumors and cancer cell lines, includ-
ing lung, breast, colon, pancreas, prostate, and gastric
cancers.11 This conserved signaling pathway, present in nu-
merous different carcinomas, provides some indication that
b-catenin signaling plays a central role in EMT regulation
(Figure 3).
In exchange for the loss of E-cadherin expression on the
cytoplasmic membrane, mesenchymal cells express N-
cadherin, which is associated with migration, invasion,
and metastasis.20 N-cadherin drives expression of fibroblast
growth factor receptors, leading to survival and resistance to
apoptosis among cells that have become disassociated from
the ECM.21 Other upregulated cell surface proteins that have
been linked to transformed cells with a mesenchymal mor-
phology include P-cadherin, cadherin-6, and carcinoem-
bryonic antigen.22508 The Journal of Thoracic and Cardiovascular SurgIn addition to cell surfacemarker alterations consistentwith
the process of EMT, several transcription factors have also
been tightly linked with EMT and are thought to play a role
in its progression. Most notably, transcriptional repressors
of E-cadherin have been isolated. These factors include the
zinc finger proteins Snail and Slug, the 2-handed zinc
E-box binding factors 1 and 2, and the basic helix-
loop-helix factors E47 (E2A gene product) and Twist (tran-
scription factor known to drive epithelial to mesenchymal
transition and metastasis). Each of these factors has been as-
sociated with EMT in human tissue specimens, and causal
roles for their activities in the process of EMT have been es-
tablished in vitro. Forcedoverexpression of each of these tran-
scription factors has been shown to induceEMT in cancer cell
lines. A detailed analysis of Snail, Slug, and E47 expressions
demonstrated that each of these transcription factors induced
similar mesenchymal phenotypes even though the specific
target genes activated or suppressed were significantly dispa-
rate, as determined by a gene Affymetrix array (Affymetrix,
Inc, Santa Clara, Calif).23 Thus the presence of EMT cells
within primary tumors of numerous different histologic types
has been described and characterized by specific protein
markers and regulators of gene transcription.
Although numerous characteristic of cells that have un-
dergone EMT have been described, as outlined previously,
mechanisms culminating in a switch from one metastable
state to the next are less well understood. One postulated
feed-forward loop contributing to EMT is outlined in
Figure 3. This model requires simultaneous transforming
growth factor b (TGFb) signaling from local inflammatory
cells, activation of the Wnt pathway, and cleavage ofery c September 2010
FIGURE 3. Proposed schematic of cellular and molecular events that can contribute to epithelial to mesenchymal transition. This schematic is not inclusive
but attempts to integrate divergent pathways and processes presented in this review. Specifically, malignant cells retain epithelial characteristics until stim-
ulated by tumor-infiltrating inflammatory cells driving release of transforming growth factor b (TGFb) and interleukin 6, which play causative role in con-
version of cells from epithelial to mesenchymal phenotype. One feed-forward loop driving epithelial to mesenchymal transition process requires simultaneous
transforming growth factor b signaling, activation of Wnt pathway, and cleavage of intercellular adherens junctions by matrix metalloproteinase 2 (MMP-2,
inset). Disruption of E-cadherin by matrix metalloproteinase 2 releases b-catenin into cytoplasm. Under normal circumstances, cytoplasmic b-catenin is rap-
idly phosphorylated by glycogen synthase kinase (GSK) 3b and marked for ubiquitination and degradation. Activation of Wnt pathway inhibits glycogen
synthase kinase 3b, allowing cytoplasmic and nuclear accumulation of b-catenin. Nuclear b-catenin acts as transcription cofactor for T-cell factor (TCF)
in concert with SMAD 2 and 3 second messengers of transforming growth factor b signaling. This transcription complex drives transcription of several ep-
ithelial to mesenchymal transition–related genes, including transcription factor Snail. Primary target for Snail is transcriptional suppression of E-cadherin,
leading to further nuclear accumulation of b-catenin, thus completing feed-forward loop and stabilizing cell in mesenchymal form.
Denlinger et al Expert Reviewintercellular adherens junctions byMMP2. The disruption of
E-cadherin by MMP2 releases b-catenin into the cytoplasm.
Under normal circumstances, cytoplasmic b-catenin is rap-
idly phosphorylated by GSK-3b and marked for ubiquitina-
tion and degradation. Activation of theWnt pathway inhibits
GSK-3b, allowing cytoplasmic and nuclear accumulation of
b-catenin. Nuclear b-catenin acts as a transcription cofactor
for T-cell factor, in concert with the SMAD (a family of
proteins involved in transforming growth factor signaling,
originally identified as class of proteins related to Sma and
Mothers against decapentaplegic protein) 2 and 3 second
messengers of TGFb signaling. This transcription complex
promotes transcription of several EMT-related genes includ-
ing vimentin, fibronectin, and the EMT -promoting tran-
scription factor Snail. A primary target for Snail is the
transcriptional suppression of E-cadherin, thus completing
the feed-forward loop and stabilizing the cell in a mesenchy-
mal form.
Local Inflammatory Induction of EMT
Our current understanding of EMT in transformed cells is
that this process is driven by local inflammatory cytokines.The Journal of Thoracic and CaEvidence supporting this phenomenon has been demon-
strated in human tumor specimens as well as in vitro inves-
tigations. Tumor budding or clusters of EMT cells are
typically located in regions of tumors associated with the in-
tense recruitment of inflammatory cells.24 Importantly, both
the presence of tumor-infiltrating macrophages and TGFb
have been associated with worse outcomes for patients
with NSCLC,25 with these correlations most pronounced
among patients with adenocarcinoma. This finding suggests
that interactions between the advancing tumor cells and local
inflammatory cells may play a role in the induction of EMT.
TGFb signaling, which has been implicated as a major
contributor to EMT among malignant cells at the advancing
front of tumors, is mediated through TGFb type I and type II
transmembrane receptors. The type I and type II TGFb
receptors form heterodimeric complexes that activate the
downstream second messengers SMAD 2 and 3, which
form complexes with SMAD 4. The SMAD 2/3–4 complex
activates the T-cell factor transcription factor, which is
tightly related to the EMT induction when bound to b-cate-
nin and SMAD.26 Cellular responses to TGFb signaling
among transformed and normal cells depends greatly onrdiovascular Surgery c Volume 140, Number 3 509
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and available transcription cofactors, which couple with
the SMAD cofactors at the time of TGFb exposure. In trans-
formed cells, TGFb binds with SMAD 2 or 3 and 4, which
couple with the transcription factor Snail. This leads to tran-
scriptional repression of E-cadherin and the Coxsackie and
adenovirus receptor, which are both critical components of
epithelial cell tight junctions that are downregulated in hu-
man cancer cells by TGFb-induced EMT events.27 In addi-
tion, TGFb signaling may also induce EMT events mediated
through type I receptors independent of SMAD secondary
messengers. Under these circumstances, the TGFb receptors
activate any of several pathways, including mitogen-
activated protein kinase and phosphoinositide 3 kinase,
both of which are linked with tumor progression.28,29
In addition to TGFb, another putative inflammatory sig-
naling molecule implicated in the induction of EMT in ma-
lignancies is interleukin (IL) 6. This signaling molecule
suppresses E-cadherin in breast cancer cells. Furthermore,
cell lines that endogenously express high levels of IL-6
have been shown to maintain a mesenchymal phenotype
characterized by low E-cadherin expression and constitu-
tively high levels of vimentin, N-cadherin, Snail, and
Twist.30 Moreover, elevated serum levels of IL-6 correlate
with advanced tumor stage, number of metastases, and over-
all poor survival among patients with breast cancer.31
Recently, circulating serum levels of inflammatory cyto-
kines have also been linked to survival among patients
with lung cancer.32 Specific cytokines most closely tied to
survival have varied according to the ethnic backgrounds
of patients with cancer. Specifically, African American
and white patients with lung cancer had worse survival rates
associated with elevated IL-6 levels. In addition, serum
levels of IL-10 and IL-12 both correlated inversely with pa-
tient survival in the African American population.32 Others
have also noted the prognostic value of inflammatory cyto-
kines. Expressions of IL-6, IL-8, and IL-10 in uninvolved
lung tissue of patients with NSCLC have been associated
with increased risk of lymph node metastasis.33 Circulating
serum levels of cytokines implicated in EMT induction in
NSCLC and other solid tumors therefore also portend worse
long-term clinical outcomes. Although some understanding
of the role of inflammatory mediators in EMT exists, these
interactions need to be further elucidated.
Invadopodia, Podosomes, and Dorsal Ruffles
It is recognized that transformed mesenchymal cells facil-
itate local invasion and distant metastasis through a process
that is initiated by degrading the integrity of the basement
membrane, which relates to the local MMP expression. Ret-
rospective analyses from patients with cancer have identified
that expression of MMPs, such as membrane-type 1 MMP
(MT1-MMP), MMP-1, MMP-2, MMP-3, MMP-7, and
MMP-13, correlate with tumor progression andmetastasis.34510 The Journal of Thoracic and Cardiovascular SurgLess is understood, however, about the mechanisms through
which local inflammation and the induction of EMT contrib-
ute to altered interactions between tumor cells and the ECM
that allow matrix degradation and motility of transformed
cells. Recently, putative mechanisms for this process have
been proposed and supported by direct observations of
tumors and experimental modeling.
Inherently mobile cells, such as macrophages and osteo-
clasts, contain various cytoplasmic membrane processes
bound to the intracellular actin skeleton called podosomes,
invadopodia, and dorsal ruffles.35 Interestingly, similar cel-
lular processes have been identified on motile EMT tumor
cells in the setting of local inflammation.36 Podosomes and
invadopodia are similar to focal adhesion in that they
possess transmembrane complexes that interact with sur-
rounding cells and the intracellular matrix. They differ, how-
ever, in that they are far more dynamic and constantly
recycle as cells migrate.35 Podosomes are rich in the struc-
tural proteins F-actin, vinculin, a-actinin, and Src, which
maintain the podosome shape and interaction with the actin
cytoskeleton.35 Podosomes also, however, contain proteins
that regulate actin polymerization such as the actin-
severing and -capping protein gelsolin, the Arp 2/3 complex,
N-WASP, and the actin-bundling protein fimbrin. The
concentration of actin regulatory proteins within podosomes
reflects the continual remodeling of these structures.35 By
way of contrast, more stable focal adhesions lack these
actin-restructuring protein complexes.
Invadopodia are structurally similar to podosomes but
demonstrate features that more clearly define their role re-
lated to ECM degradation and cell migration.37 Invadopodia
were first identified at the exact locations where ECM deg-
radation was occurring. Later, it was discovered that they
contain an enriched presence of MMPs responsible for
ECM degradation as well as modulating extracellular signal-
ing cascades.38 Specifically, MT1-MMP localizes to invado-
podia, where it is an essential component and appears to play
a pivotal role in pathologic cell invasion and migration.39
MT1-MMP activity has also been found to be essential for
in vitro migration of cells through a Matrigel (BD Biosci-
ences, San Jose, Calif) matrix.40 Although MT1-MMP is
normally expressed in cells of mesenchymal origin, includ-
ing fibroblasts, muscular cells, and osteoblasts, this protein
is also expressed on cells from numerous epithelium-based
solid tumors. Experimental in vitro studies have shown
that interference with either the MMP activity or actin re-
modeling of invadopodia suppresses ECM degradation.
This information suggest a critical role for invadopodia in
contributing to characteristics and behavior consistent with
the EMT phenotype.
MT1-MMP expression was initially reported in lung can-
cer cells and fibroblasts adjacent to the advancing tumor
front.41 More recent studies have confirmed this finding
and also identified the accumulation of MMP-2 at advancingery c September 2010
Denlinger et al Expert Reviewtumor fronts.42 Similar patterns of MT1-MMP expression
have also been described in other carcinomas, including gas-
tric, colon, liver, breast, bladder, thyroid, head and neck,
ovarian, and cervical cancers. One of the primary functions
of MT1-MMP, in addition to ECM degradation, is the cleav-
age and activation of the MMP-2 precursor. The expressions
of both MT1-MMP and MMP-2 correlate with poor progno-
sis and have been postulated to result from Wnt signaling,
which is also an upstream activator of EMT.39 Strong sup-
porting data for the development of invadopodia in cells
that have undergone EMT has been found in squamous
cell carcinomas of the head and neck.43 These tumor speci-
mens demonstrate an exchange of podosome structures in
noninvasive tumors for invadopodia in the invasive compo-
nents of tumors where EMT has occurred. Collectively,
these data support the role of invadopodia and podosomes
in contributing to the activity and behavior of EMT cells
in cancer.
Growth Arrest
Although the presence of EMT foci within primary
tumors is indicative of poor outcomes, EMT cells are not
particularly aggressive while in the mesenchymal state.44
In fact, EMT cells undergo cell cycle arrest. Transcription
factors associated with EMT influence expression of numer-
ous genes. Although EMT-related transcription factors were
initially thought to primarily silence gene expression, signif-
icantly more genes appear to be directly activated than in-
hibited by these factors. The first recognized targets of
transcriptional suppression in EMT cells were epithelial
cell surface markers; however, EMT-associated transcrip-
tion factors have been shown to upregulate transcription of
numerous factors involved in cell cycle regulation. In fact,
nearly a fourth of all genes regulated by Snail, Slug, and
E47 are involved in cell cycle progression.23 Included
among this list of genes activated during EMT are the cell
cycle checkpoint proteins p21 and p15.45
Growth arrest among transformed mesenchymal cells is
problematic from a treatment standpoint for 2 reasons.
Most importantly, growth arrested mesenchymal cells are in-
herently resistant to the cytotoxic effects of chemotherapy
designed to kill rapidly dividing cells. Thus the EMT cell
population may represent ‘‘stem cells’’ that can repopulate
tumors, leading to cancer recurrence after treatment. Fur-
thermore, because the EMT phenotype is completely revers-
ible, cells are able to revert back to an epithelial form
characterized by rapid growth. EMT cells therefore repre-
sent the cancer’s ability to recur.
MESENCHYMALTO EPITHELIAL TRANSITION
Micrometastatic mesenchymal cell colonies revert back to
an epithelial phenotype through a process of MET as the re-
sult of poorly elucidated stimuli that cause them to begin to
grow rapidly, invade surrounding tissues, and ultimatelyThe Journal of Thoracic and Calead to the patient’s death.46 Determination of mechanisms
responsible for MET is clinically relevant because this
process appears crucial for micrometastases to develop
into significant disease. In vitro studies of colon cancer
cell lines provide some evidence that the MET phenomenon
may result from enhanced cell density and paracrine stimu-
lation from neighboring cells.47 Patient-based data are lack-
ing, however, simply because MET events are likely to
occur in very small foci of metastatic disease that have yet
to become clinically detectable. Once a metastasis has
achieved a size sufficient for clinical recognition, the vast
majority of cells populating the metastasis are already in
the epithelial form, and MET has already occurred.
Widely disseminated cancer cells have been identified in
the blood and bone marrow of patients with breast cancer
without clinical evidence of metastatic disease, and in
some patients these disseminated tumor cells may remain
dormant throughout the patient’s life span.48 Recent studies
have also identified disseminated tumor cells in the bone
marrow of patients with NSCLC. Moreover, genomic
changes present within disseminated tumor cells were con-
sistent with mutations identified in brain metastases of the
same patients, suggesting that a similar population of dis-
seminated cells was present in both the bone marrow and
brain tissue, leading to appreciable brain metastases.49 These
observations provide convincing evidence that subclinical
micrometastases can in fact develop into clinically signifi-
cant metastatic disease. It is therefore conceivable that
NSCLC cells disseminate in a mesenchymal form and sub-
sequently reactivate with an epithelial phenotype, leading
to metastatic growth.
Ongoing investigations are required to determine the cir-
cumstances under which MET occurs in vitro and whether
this process plays a meaningful role in the establishment
of metastatic disease in patients with NSCLC and other can-
cers. An important clinical question is whether stimuli lead-
ing to MET events can be arrested either pharmacologically
or with antibodies targeting necessary elements of the MET
process.
SUMMARY
Substantial evidence supports the phenomenon of EMT
existing in numerous types of carcinomas, including lung
cancer. Furthermore, correlative data support the hypothesis
that EMT represents a critical event in tumor progression,
despite the fact that the EMT cells are not particularly ag-
gressive while in the mesenchymal state. Ongoing studies
will be required to further elucidate the role of EMT in the
invasion and metastasis of lung and other cancers. In addi-
tion, ongoing investigations will determine how the pres-
ence of transformed mesenchymal cells can be exploited
for diagnostic and treatment purposes in patients with lung
cancer. Currently, investigations related to delivering
targeted therapy toward markers for EMT are only in therdiovascular Surgery c Volume 140, Number 3 511
Expert Review Denlinger et alpreclinical stages of development. Development of strate-
gies that target this cell population may contribute signifi-
cantly to our lung cancer treatment armamentarium,
however, because EMT creates a relatively unique cell pop-
ulation in the adult patient. Furthermore, understanding the
mesenchymal component of epithelium-derived tumors is
important because these cells may represent a chemoresistant
component with the potential to both repopulate the primary
tumor and metastasize after treatment. Certainly, collabora-
tive investigations between clinicians and basic science in-
vestigators are required to establish a better understanding
of the process of EMT and how it relates to the progression
of lung cancer, as well as other solid tumor malignancies.
We thank Kaeyln Hawkins for her contributions in creating and
editing Figure 1 of this article.References
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